<DOC>
	<DOCNO>NCT00002514</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining chemotherapy allogeneic autologous stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . It yet know whether stem cell transplantation effective standard chemotherapy treat acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial study well stem cell transplantation work compare standard combination chemotherapy treat patient acute lymphoblastic leukemia first remission .</brief_summary>
	<brief_title>Stem Cell Transplantation Compared With Standard Chemotherapy Treating Patients With Acute Lymphoblastic Leukemia First Remission</brief_title>
	<detailed_description>OBJECTIVES : - Compare duration complete remission ( CR ) survival patient acute lymphoblastic leukemia first remission treat allogeneic autologous stem cell transplantation ( SCT ) vs conventional consolidation maintenance chemotherapy . - Compare overall treatment outcomes patient treat regimen . - Determine effect imatinib mesylate give induction therapy Philadelphia ( Ph ) chromosome-positive patient CR . - Determine benefit allogeneic autologous SCT imatinib mesylate Ph chromosome-positive patient . - Determine benefit additional imatinib mesylate administer allogeneic autologous SCT Ph chromosome-positive patient . - Determine minimal residual disease Ph chromosome-positive patient treatment imatinib mesylate . - Determine clinical resistance imatinib mesylate cause BCR-ABL gene amplification mutation Ph chromosome-positive patient . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 50 vs 50 ) , time achieve complete remission ( CR ) ( 4 week less vs 4 week ) , Philadelphia ( Ph ) chromosome status ( positive v negative ) . - First induction therapy : Patients receive daunorubicin ( DNR ) IV 15-30 minute vincristine ( VCR ) IV 3-5 minute day 1 , 8 , 15 , 22 ; oral prednisone ( PRED ) daily day 1-28 ; asparaginase ( ASP ) IV 30 minute intramuscularly day 17-28 . Patients CNS leukemia presentation also receive methotrexate ( MTX ) intrathecally ( IT ) via Ommaya reservoir weekly CSF clear . Patients without CNS leukemia presentation receive MTX IT day 23 . - Second induction therapy : Beginning immediately first induction therapy , patient receive cyclophosphamide ( CTX ) IV 30 minute day 1 , 15 , 29 ; cytarabine ( ARA-C ) IV 30 minute day 1-4 , 8-11 , 15-18 , 22-25 ; oral mercaptopurine ( MP ) daily day 1-28 . Patients CNS leukemia presentation also undergo concurrent craniospinal irradiation . Patients without CNS leukemia presentation receive MTX IT day 1 , 8 , 15 , 22 . Patients Ph chromosome-positive status receive oral imatinib mesylate daily least 28 day ( day 1-28 ) . Patients Ph chromosome-positive status CR second induction therapy proceed group I autologous allogeneic stem cell transplantation ( SCT ) . Patients Ph chromosome-negative status CR second induction therapy proceed group II . - Group I ( Ph chromosome-positive patient ) : - Autologous SCT : Patients receive high-dose consolidation/mobilization chemotherapy comprise ARA-C IV 3 hour day 1-3 mitoxantrone IV immediately ARA-C administration day 1 2 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 5 continue blood count recover . Patients undergo peripheral blood stem cell collection bone marrow harvest . Patients receive preparative therapy comprise total body irradiation twice daily ( 5-10 hour apart ) day -6 -4 high-dose etoposide ( VP-16 ) IV 4 hour day -3 . Male patient also undergo radiotherapy boost testis day -6 . Patients undergo autologous SCT day 0 receive sargramostim ( GM-CSF ) SC daily begin 6 hour completion SCT continue blood count recover . - Allogeneic SCT : Patients receive preparative regimen autologous SCT undergo allogeneic SCT day 0 . Patients receive GM-CSF autologous SCT . - Post-SCT imatinib mesylate therapy : After recovery autologous allogeneic SCT , patient receive oral imatinib mesylate daily . Imatinib mesylate therapy continue absence disease progression unacceptable toxicity . - Group II ( Ph chromosome-negative patient ) : - Intensification therapy : Beginning 4 week completion second induction therapy , patient receive high-dose MTX IV 2 hour day 1 , 8 , 22 ; leucovorin calcium IV every 6 hour 4 dos orally every 6 hour 12 dos begin 22-24 hour MTX infusion ; ASP IV 30 minute day 2 , 9 , 23 . Patients ≤ 50 year age histocompatible donor proceed allogeneic SCT undergo allogeneic SCT group I . Patients ≤ 50 year age without appropriate donor randomize 1 2 treatment arm . - Arm I ( conventional consolidation/maintenance therapy ) : - Conventional consolidation therapy : During course 1 , patient receive ARA-C IV 30 minute VP-16 IV 1 hour day 1-5 ; VCR IV day 1 , 8 , 15 , 22 ; oral dexamethasone day 1-28 . During course 2 ( begin 4 week initiation course 1 blood count recover ) , patient receive ARA-C VP-16 course 1 . During course 3 ( begin 4 week initiation course 2 blood count recover ) , patient receive DNR IV day 1 , 8 , 15 , 22 ; CTX IV 30 minute day 29 ; ARA-C IV 30 minute day 31-34 38-41 ; oral thioguanine day 29-42 . During course 4 ( begin 8 week initiation course 3 blood count recover ) , patient receive treatment course 2 . - Maintenance therapy : Beginning 4 week initiation course 4 consolidation therapy blood count recover , patient receive oral MP daily ; MTX orally IV weekly ; VCR IV every 12 week ; oral PRED 5 day every 12 week . Maintenance therapy continue 2.5 year initiation intensification therapy . - Arm II ( autologous SCT ) : Patients undergo autologous SCT group I exception high-dose consolidation/mobilization chemotherapy . Patients follow every 6 month 2 year . PROJECTED ACCRUAL : Approximately 40 patient per year accrue group I ( Philadelphia [ Ph ] chromosome-positive patient ) study . Approximately 550 patient accrue group II ( Ph chromosome-negative patient ) study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphoblastic leukemia ( ALL ) More 25 % lymphoblasts bone marrow Patients myeloid antigen expression AND unequivocal lymphoid immunophenotype eligible Philadelphia ( Ph ) chromosome status determine cytogenetics , fluorescence situ hybridization ( FISH ) , and/or RNA analysis Patients determine Ph chromosome negative cytogenetics , positive BCRABL FISH polymerase chain reaction consider Ph chromosome positive Patients Ph chromosomepositive disease may age 65 No myelodysplasia antecedent hematologic disorder Patients age 50 must HLA type induction therapy study treatment OR provide write explanation undergo HLA type A B typing require C DR type do feasible Allogeneic stem cell transplantation patient must meet following criterion : Appropriate HLA histocompatible donor available Ph chromosomenegative patient must HLA identical sibling Ph chromosomepositive patient must HLA identical , HLAmatched unrelated , haploidentical relate donor Postinduction therapy : CSF negative leukemia No occult overt leukemic meningitis Documented complete remission PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Induction therapy : Not specify Postinduction therapy : 01 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Induction therapy : Direct bilirubin ≤ 2.0 mg/dL Postinduction therapy : Direct bilirubin &lt; 2.0 mg/dL SGPT SGOT &lt; 3 time normal Renal : Induction therapy : Creatinine &lt; 2 mg/dL Postinduction therapy : Creatinine ≤ 2 mg/dL Creatinine clearance ≥ 60 mL/min Cardiovascular : Induction postinduction therapy : No significant cardiac disease require digoxin and/or diuretics No major ventricular dysrhythmia require medication No ischemic heart disease require medication Postinduction therapy : Cardiac ejection fraction ≥ 50 % patient consideration transplantation Pulmonary : Induction therapy : Not specify Postinduction therapy : FEV_1 ≥ 60 % predict patient consideration transplantation DLCO ≥ 50 % predict patient consideration transplantation Other : Induction postinduction therapy : HIV negative No concurrent organ damage medical problem ( e.g. , psychiatric disorder drug abuse ) would preclude study therapy Not pregnant Postinduction therapy : No persistent infection PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent umbilical cord allogeneic transplantation Chemotherapy : Not specify Endocrine therapy : Prior corticosteroid ALL allow Radiotherapy : Not specify Surgery : Not specify Other : Induction postinduction therapy : No prior therapy ALL Postinduction therapy : No concurrent antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
</DOC>